Conference Calendar - The 33rd International Papillomavirus Conference

Times are stated in CEST (GMT + 2 / UTC + 2)
Every effort has been made to convert the IPVC 2020 scientific program into a fully virtual program. Thank you to all the presenters who have submitted their recordings in advance. These are available as on-demand webcasts in the interactive program on the virtual conference platform. Please note that some presenters were not able to pre-record their presentations, therefore there are still some sessions with missing presentations.

To view the pre-conference workshops, you need to register for them separately. Please contact: reg_ipvc20@kenes.com
You will then receive an email with instructions on how to login to the workshops’ platform.

Displaying One Session

View

Public Health Oral Session

01080 - Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening (ID 57)

Session Type

Public Health Oral Session

Session Date

07/24/2020

Session Time

16:00 - 17:40

Room

Hall D

Chair(s)

Watch Stream
Session Webcast

Session Webcast

[{"name":"PREDICTED IMPACT OF HPV VACCINATION AND PRIMARY HPV SCREENING ON ADVERSE PREGNANCY OUTCOMES IN AUSTRALIA 2005-2070: MODELLING IN A HIGH INCOME, HIGH VACCINATION COVERAGE COUNTRY \u003Csmall\u003E(ID 710)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":710,"presentation":"PREDICTED IMPACT OF HPV VACCINATION AND PRIMARY HPV SCREENING ON ADVERSE PREGNANCY OUTCOMES IN AUSTRALIA 2005-2070: MODELLING IN A HIGH INCOME, HIGH VACCINATION COVERAGE COUNTRY \u003Csmall\u003E(ID 710)\u003C\/small\u003E","session":"Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening","presenter":"Susan E. Yuill (Australia)","photo":""},"playlist":[{"name":"PREDICTED IMPACT OF HPV VACCINATION AND PRIMARY HPV SCREENING ON ADVERSE PREGNANCY OUTCOMES IN AUSTR","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/GMT20200618-045318_Susan-Yuil_1920x1080-0.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/57\/GMT20200618-045318_Susan-Yuil_1920x1080-0.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/79E106E8.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/GMT20200618-045318_Susan-Yuil_1920x1080-0.vtt"}]},{"name":"EFFECT OF HPV VACCINATION ON CERVICAL LESIONS IN OPPORTUNISTIC CERVICAL SCREENING AMONG YOUNG WOMEN IN THE NETHERLANDS \u003Csmall\u003E(ID 816)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":816,"presentation":"EFFECT OF HPV VACCINATION ON CERVICAL LESIONS IN OPPORTUNISTIC CERVICAL SCREENING AMONG YOUNG WOMEN IN THE NETHERLANDS \u003Csmall\u003E(ID 816)\u003C\/small\u003E","session":"Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening","presenter":"Tessa Schurink-van 't Klooster (Netherlands)","photo":""},"playlist":[{"name":"EFFECT OF HPV VACCINATION ON CERVICAL LESIONS IN OPPORTUNISTIC CERVICAL SCREENING AMONG YOUNG WOMEN ","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/816.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/57\/816.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/8AA51430.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/816.vtt"}]},{"name":"REDUCTION IN CIN3+ AT SECOND AND SUBSEQUENT SCREENS IN WOMEN IMMUNISED WITH CERVARIX\u00ae \u003Csmall\u003E(ID 1484)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1484,"presentation":"REDUCTION IN CIN3+ AT SECOND AND SUBSEQUENT SCREENS IN WOMEN IMMUNISED WITH CERVARIX\u00ae \u003Csmall\u003E(ID 1484)\u003C\/small\u003E","session":"Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening","presenter":"Timothy Palmer (United Kingdom)","photo":""},"playlist":[{"name":"REDUCTION IN CIN3 AT SECOND AND SUBSEQUENT SCREENS IN WOMEN IMMUNISED WITH CERVARIX","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/1484 - Tim Palmer - IPVC20 - REDUCTION IN CIN3.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/57\/1484 - Tim Palmer - IPVC20 - REDUCTION IN CIN3.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/7F028B19.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/1484 - Tim Palmer - IPVC20 - REDUCTION IN CIN3.vtt"}]},{"name":"A LINKAGE STUDY OF HUMAN PAPILLOMAVIRUS (HPV) VACCINATION AND PAP SMEAR CERVICAL CANCER SCREENING IN FERRARA, ITALY. \u003Csmall\u003E(ID 1162)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1162,"presentation":"A LINKAGE STUDY OF HUMAN PAPILLOMAVIRUS (HPV) VACCINATION AND PAP SMEAR CERVICAL CANCER SCREENING IN FERRARA, ITALY. \u003Csmall\u003E(ID 1162)\u003C\/small\u003E","session":"Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening","presenter":"Cecilia Acuti Martellucci (Japan)","photo":""},"playlist":[{"name":"A LINKAGE STUDY OF HUMAN PAPILLOMAVIRUS (HPV) VACCINATION AND PAP SMEAR CERVICAL CANCER SCREENING IN","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/3 Ready.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/57\/3 Ready.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/7B85D63E.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/3 Ready.vtt"}]},{"name":"USING CANCER REGISTRIES TO ASSESS HPV VACCINE IMPACT ON VULVAR, VAGINAL, AND ANAL PRECANCERS IN FEMALES UNDER 40 YEARS OF AGE, UNITED STATES 2000-2016 \u003Csmall\u003E(ID 1324)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":1324,"presentation":"USING CANCER REGISTRIES TO ASSESS HPV VACCINE IMPACT ON VULVAR, VAGINAL, AND ANAL PRECANCERS IN FEMALES UNDER 40 YEARS OF AGE, UNITED STATES 2000-2016 \u003Csmall\u003E(ID 1324)\u003C\/small\u003E","session":"Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening","presenter":"Jacqueline M. Mix (United States of America)","photo":""},"playlist":[{"name":"USING CANCER REGISTRIES TO ASSESS HPV VACCINE IMPACT ON VULVAR, VAGINAL, AND ANAL PRECANCERS IN FEMA","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/IPVC 20 - P1324 - S1080 - Jacqueline Mix - joined.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/57\/IPVC 20 - P1324 - S1080 - Jacqueline Mix - joined.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/136B36FA.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/IPVC 20 - P1324 - S1080 - Jacqueline Mix - joined.vtt"}]},{"name":"ESTIMATING THE EFFECT OF HPV VACCINATION ON THE LIFETIME RISK OF SCREEN-DETECTED CERVICAL PRECANCER \u003Csmall\u003E(ID 801)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":801,"presentation":"ESTIMATING THE EFFECT OF HPV VACCINATION ON THE LIFETIME RISK OF SCREEN-DETECTED CERVICAL PRECANCER \u003Csmall\u003E(ID 801)\u003C\/small\u003E","session":"Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening","presenter":"Federica Inturrisi (Netherlands)","photo":""},"playlist":[{"name":"Federica Inturrisi - IPVC20 - 801","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/Federica Inturrisi - IPVC20 - 801.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/57\/Federica Inturrisi - IPVC20 - 801.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/70C5DF1B.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/Federica Inturrisi - IPVC20 - 801.vtt"}]},{"name":"DOES THE GENOTYPE-SPECIFIC CIN2+ RISK IN CERVICAL SCREENING CHANGE IN PARTLY HPV-VACCINATED COHORTS? \u003Csmall\u003E(ID 290)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":290,"presentation":"DOES THE GENOTYPE-SPECIFIC CIN2+ RISK IN CERVICAL SCREENING CHANGE IN PARTLY HPV-VACCINATED COHORTS? \u003Csmall\u003E(ID 290)\u003C\/small\u003E","session":"Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening","presenter":"Johannes A. Bogaards (Netherlands)","photo":""},"playlist":[{"name":"DOES THE GENOTYPE-SPECIFIC CIN2+ RISK IN CERVICAL SCREENING CHANGE IN PARTLY HPV-VACCINATED COHORTS?","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/Hans Bogaards IPVC20 PRESENTATION id 290.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/57\/Hans Bogaards IPVC20 PRESENTATION id 290.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/A842F5E8.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/Hans Bogaards IPVC20 PRESENTATION id 290.vtt"}]},{"name":"HPV VACCINE EFFECTIVENESS AND CROSS-PROTECTION BY AGE AT VACCINATION, TIMING OF SEXUAL INITIATION IN RELATION TO VACCINATION, AND NUMBER OF DOSES IN A REAL-WORLD SETTING \u003Csmall\u003E(ID 670)\u003C\/small\u003E","mode":"playlist","public":true,"info":{"id":670,"presentation":"HPV VACCINE EFFECTIVENESS AND CROSS-PROTECTION BY AGE AT VACCINATION, TIMING OF SEXUAL INITIATION IN RELATION TO VACCINATION, AND NUMBER OF DOSES IN A REAL-WORLD SETTING \u003Csmall\u003E(ID 670)\u003C\/small\u003E","session":"Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening","presenter":"Jessica A. Kahn (United States of America)","photo":""},"playlist":[{"name":"HPV VACCINE EFFECTIVENESS AND CROSS-PROTECTION BY AGE AT VACCINATION, TIMING OF SEXUAL INITIATION IN","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/GMT20200610-145251_Jessica-Ka_1686x768.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/ipvc20\/57\/GMT20200610-145251_Jessica-Ka_1686x768.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/1D2A9290.jpg","data":[],"tracks":[],"chapters":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/ipvc20\/57\/GMT20200610-145251_Jessica-Ka_1686x768.vtt"}]}]

Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening Hall D

PREDICTED IMPACT OF HPV VACCINATION AND PRIMARY HPV SCREENING ON ADVERSE PREGNANCY OUTCOMES IN AUSTRALIA 2005-2070: MODELLING IN A HIGH INCOME, HIGH VACCINATION COVERAGE COUNTRY (ID 710)

Session Date

07/24/2020

Session Time

16:00 - 17:40

Room

Hall D

Session Type

Public Health Oral Session

Session Name

Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening

Lecture Time

16:00 - 16:12

Presenter

Susan E. Yuill (Australia)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening Hall D

EFFECT OF HPV VACCINATION ON CERVICAL LESIONS IN OPPORTUNISTIC CERVICAL SCREENING AMONG YOUNG WOMEN IN THE NETHERLANDS (ID 816)

Session Date

07/24/2020

Session Time

16:00 - 17:40

Room

Hall D

Session Type

Public Health Oral Session

Session Name

Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening

Lecture Time

16:12 - 16:24

Presenter

Tessa Schurink-van 't Klooster (Netherlands)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening Hall D

REDUCTION IN CIN3+ AT SECOND AND SUBSEQUENT SCREENS IN WOMEN IMMUNISED WITH CERVARIX® (ID 1484)

Session Date

07/24/2020

Session Time

16:00 - 17:40

Room

Hall D

Session Type

Public Health Oral Session

Session Name

Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening

Lecture Time

16:24 - 16:36

Presenter

Timothy Palmer (United Kingdom)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening Hall D

A LINKAGE STUDY OF HUMAN PAPILLOMAVIRUS (HPV) VACCINATION AND PAP SMEAR CERVICAL CANCER SCREENING IN FERRARA, ITALY. (ID 1162)

Session Date

07/24/2020

Session Time

16:00 - 17:40

Room

Hall D

Session Type

Public Health Oral Session

Session Name

Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening

Lecture Time

16:36 - 16:48

Presenter

Cecilia Acuti Martellucci (Japan)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening Hall D

USING CANCER REGISTRIES TO ASSESS HPV VACCINE IMPACT ON VULVAR, VAGINAL, AND ANAL PRECANCERS IN FEMALES UNDER 40 YEARS OF AGE, UNITED STATES 2000-2016 (ID 1324)

Session Date

07/24/2020

Session Time

16:00 - 17:40

Room

Hall D

Session Type

Public Health Oral Session

Session Name

Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening

Lecture Time

16:48 - 17:00

Presenter

Jacqueline M. Mix (United States of America)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening Hall D

ESTIMATING THE EFFECT OF HPV VACCINATION ON THE LIFETIME RISK OF SCREEN-DETECTED CERVICAL PRECANCER (ID 801)

Session Date

07/24/2020

Session Time

16:00 - 17:40

Room

Hall D

Session Type

Public Health Oral Session

Session Name

Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening

Lecture Time

17:00 - 17:12

Presenter

Federica Inturrisi (Netherlands)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening Hall D

DOES THE GENOTYPE-SPECIFIC CIN2+ RISK IN CERVICAL SCREENING CHANGE IN PARTLY HPV-VACCINATED COHORTS? (ID 290)

Session Date

07/24/2020

Session Time

16:00 - 17:40

Room

Hall D

Session Type

Public Health Oral Session

Session Name

Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening

Lecture Time

17:12 - 17:24

Presenter

Johannes A. Bogaards (Netherlands)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening Hall D

HPV VACCINE EFFECTIVENESS AND CROSS-PROTECTION BY AGE AT VACCINATION, TIMING OF SEXUAL INITIATION IN RELATION TO VACCINATION, AND NUMBER OF DOSES IN A REAL-WORLD SETTING (ID 670)

Session Date

07/24/2020

Session Time

16:00 - 17:40

Room

Hall D

Session Type

Public Health Oral Session

Session Name

Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening

Lecture Time

17:24 - 17:36

Presenter

Jessica A. Kahn (United States of America)

Authors

Webcast

Webcast

[session]

[presentation]

[presenter]

Hide

Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening Hall D

Online Chat Q&A for this session is called: PUBLIC HEALTH ORAL SESSION 18: VACCINATION AND SCREENING. IMPACT OF HPV VACCINATION ON CERVICAL CANCER SCREENING. You can join the online chat Q&A and discussions for this session by going back to the Lobby and entering the Networking Lounge. Speakers are encouraged to be online in the chat room at the time this session is stated to end. All times are in CEST. (ID 1816)

Session Date

07/24/2020

Session Time

16:00 - 17:40

Room

Hall D

Session Type

Public Health Oral Session

Session Name

Oral Session 18: VACCINATION AND SCREENING. Impact of HPV vaccination on cervical cancer screening

Lecture Time

17:36 - 17:36